Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) have been given an average rating of "Moderate Buy" by the twelve research firms that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $25.50.

Several analysts recently issued reports on the company. Scotiabank dropped their target price on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating on the stock in a report on Wednesday, January 8th. UBS Group dropped their price objective on Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. StockNews.com raised shares of Kura Oncology from a "hold" rating to a "buy" rating in a research note on Friday, April 4th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. Finally, Wedbush reissued an "outperform" rating and issued a $36.00 price objective on shares of Kura Oncology in a research report on Tuesday, April 8th.

Kura Oncology Stock Up 2.5 %

Shares of KURA traded up $0.14 during mid-day trading on Wednesday, hitting $5.77. 2,111,548 shares of the company's stock were exchanged, compared to its average volume of 1,125,052. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 52 week low of $5.41 and a 52 week high of $23.48. The company has a market cap of $465.96 million, a PE ratio of -2.44 and a beta of 0.83. The company has a 50-day simple moving average of $7.36 and a 200 day simple moving average of $10.80.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. On average, research analysts forecast that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Transactions at Kura Oncology

In other news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares of the company's stock, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the company's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock worth $92,307 over the last quarter. Company insiders own 5.50% of the company's stock.

Institutional Trading of Kura Oncology

A number of institutional investors have recently bought and sold shares of KURA. Virtus ETF Advisers LLC raised its position in shares of Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after buying an additional 3,061 shares in the last quarter. Harbor Advisors LLC acquired a new position in Kura Oncology in the 4th quarter valued at $87,000. E Fund Management Co. Ltd. bought a new stake in shares of Kura Oncology during the 4th quarter valued at $90,000. Corton Capital Inc. acquired a new stake in shares of Kura Oncology during the 4th quarter worth $99,000. Finally, Optimize Financial Inc bought a new position in shares of Kura Oncology in the fourth quarter worth $100,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.